Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-07-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于申请向特定对象发行股票的审核问询函回复（三次修订稿）的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the company's response to an inquiry letter from the Shenzhen Stock Exchange about its application for a private placement of shares. It references multiple previous announcements and responses to the inquiry letter, including revised drafts. The document states that the issuance of shares is subject to further approval by the stock exchange and the China Securities Regulatory Commission. The document is short (1033 characters) and primarily serves as a disclosure or update about the ongoing review process and regulatory compliance, rather than containing detailed financial data or the actual issuance itself. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's financing activities and capital structure changes through a private placement of shares.
2021-07-19 Chinese
北京市康达律师事务所关于公司向特定对象发行股票的补充法律意见书（一）（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a company's specific stock issuance to particular investors. It discusses legal compliance, share issuance details, asset evaluations, and regulatory inquiries related to the issuance. The document is titled as a "Supplementary Legal Opinion Letter" and contains extensive legal analysis and verification of the issuance process, pricing, and compliance with securities regulations. It is not a financial report, earnings release, or management discussion, but a legal opinion related to capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-07-15 Chinese
公司及中国银河证券股份有限公司关于审核问询函的回复（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application for a private placement of shares (specific object issuance). It includes extensive information about the company's business qualifications, project descriptions, financial data, and compliance with regulatory requirements. The content focuses on the company's capital raising activities, use of proceeds, and related financial and operational details. This aligns with a Capital/Financing Update filing, which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-07-15 Chinese
关于申请向特定对象发行股票的审核问询函回复（二次修订稿）的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the company's response to a review inquiry letter from the Shenzhen Stock Exchange about its application for a private placement of shares. It references previous filings and responses to the inquiry letter and states that the matter is still under review and subject to regulatory approval. The document is short (1017 characters) and primarily serves as a notice about the submission and revision of responses to regulatory inquiries related to a capital raising activity (private placement of shares). It does not contain financial statements or detailed financial data but is an update on the financing process and regulatory review. Therefore, it fits best under Capital/Financing Update (CAP).
2021-07-15 Chinese
向特定对象发行股票募集说明书（三次修订稿）
Capital/Financing Update Classification · 100% confidence The document is titled "向特定对象发行股票募集说明书" which translates to "Private Placement Stock Issuance Prospectus" or "Offering Circular for Private Placement of Shares." It contains detailed information about the issuance of new shares to specific investors, including background, approval procedures, risk factors, use of proceeds, shareholder structure, and legal and regulatory compliance. The document is lengthy (15,000 characters) and includes detailed disclosures typical of a capital raising or financing document. It is not an annual report, earnings release, or management discussion. It is not a proxy statement or voting results announcement. It is clearly an offering document related to capital raising through share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-07-15 Chinese
中国银河证券股份有限公司关于公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled '上市保荐书' which translates to 'Listing Sponsorship Letter' or 'Sponsorship Document for Stock Issuance'. It is issued by a securities company (中国银河证券股份有限公司) acting as the sponsor for Tianjin Ringpu Biotechnology Co., Ltd. regarding a specific stock issuance to particular investors. The content includes detailed information about the issuer, the stock issuance specifics, financial data, business risks, and regulatory compliance. This type of document is typically related to capital raising activities and the process of issuing new shares to specific investors, which aligns with announcements or documents related to capital/financing updates. It is not an annual report, earnings release, or management report, nor is it a proxy, voting result, or legal proceeding. The document is comprehensive and not a mere announcement of a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-07-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.